

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bruno DE LIGNIERES

Title: TREATMENT OF MASTALGIA WITH 4-HYDROXY TAMOXIFEN

Appl. No.: 10/734,640

Filing Date: 12/15/2003

Examiner: U. Ramachandran

Art Unit: 1627

Confirmation 9061

Number:

APPLICANTS' RESPONSE TO EXAMINER'S REASONS FOR ALLOWANCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Notice of Allowance mailed February 2, 2010, in the captioned application includes an Examiner's Statement of Reasons for Allowance. To the extent that the Examiner's Statement may focus on or highlight specific aspects of the invention or specific arguments made during prosecution, Applicant responds that it is the invention as a whole that is patentable, as shown by the record as a whole. Moreover, to the extent that the Examiner's Statement may identify specific references as the "closest prior art," or may characterize the teachings of cited references, Applicant responds that the references speak for themselves. To the extent that the Examiner's Statement may find that the invention is distinguished from specific cited references, Applicant responds that the invention is believed to be patentable over all cited references.

In particular, the record shows that methods of treatment for mastalgia, comprising administering percutaneously to the breasts of a patient having mastalgia a composition

comprising 4-hydroxy tamoxifen as the sole therapeutically active ingredient, at a dose of at least 1.5 mg/day 4-hydroxy tamoxifen, are not taught or suggested by any combination of the cited references.

Respectfully submitted,

Date March 23, 2010

By Courtenay C. Brinckerhoff

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 295-4094
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff
Attorney for Applicant
Registration No. 37,288